We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Powerful AI Risk Assessment Tool Predicts Outcomes in Heart Failure Patients

By HospiMedica International staff writers
Posted on 16 May 2024
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)
Image: The new risk assessment tool determines patient-specific risks of developing unfavorable outcomes with heart failure (Photo courtesy of 123RF)

Heart failure is a serious condition where the heart cannot pump sufficient blood to meet the body's needs, leading to symptoms like fatigue, weakness, and swelling in the legs and feet, and it can ultimately result in death. It is a progressive disease, making it crucial for healthcare providers to identify patients at high risk of worsening outcomes. Now, researchers have introduced a potent new risk assessment tool designed to predict the prognosis of patients with heart failure. This tool marks an advancement over previous methods by utilizing machine learning (ML) and artificial intelligence (AI) to assess individual risks of developing serious complications associated with heart failure.

This innovative model was developed by researchers at the University of Virginia Health System (Charlottesville, VA, USA), using anonymized data from thousands of patients who participated in heart failure clinical trials previously sponsored by the National Institutes of Health’s National Heart, Lung, and Blood Institute. When evaluated, the model proved more effective than existing predictors in forecasting outcomes for a wide range of patients, including the likelihood of requiring heart surgery or a transplant, the risk of rehospitalization, and the risk of mortality. The success of the model is attributed to the integration of ML/AI technologies and the inclusion of hemodynamic clinical data, which detail how blood moves through the heart, lungs, and other parts of the body. By applying this model, doctors can tailor treatment more precisely to each patient's needs, potentially extending and improving the quality of their lives, according to the researchers.

“Heart failure is a progressive condition that affects not only quality of life but quantity as well. All heart failure patients are not the same. Each patient is on a spectrum along the continuum of risk of suffering adverse outcomes,” said researcher Sula Mazimba, MD, a heart failure expert. “Identifying the degree of risk for each patient promises to help clinicians tailor therapies to improve outcomes.”

“This model presents a breakthrough because it ingests complex sets of data and can make decisions even among missing and conflicting factors,” added researcher Josephine Lamp, of the University of Virginia School of Engineering’s Department of Computer Science. “It is really exciting because the model intelligently presents and summarizes risk factors reducing decision burden so clinicians can quickly make treatment decisions.”

Related Links:
UVA Health

Gold Member
12-Channel ECG
CM1200B
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Radial Artery Compression Device
TR Band
New
ow Frequency Pulse Massager
ET10 L

Channels

Surgical Techniques

view channel
Image: The proposed hyperspectral endoscopic imaging system includes a spectral LED array in the catheter tip (Courtesy of N. Modir et al., doi 10.1117/1.JMI.12.3.035002)

LED-Based Imaging System Could Transform Cancer Detection in Endoscopy

Gastrointestinal cancers remain one of the most common and challenging forms of cancer to diagnose accurately. Despite the widespread use of endoscopy for screening and diagnosis, the procedure still misses... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: A research collaboration aims to further advance findings in human genomics research in cardiovascular diseases (Photo courtesy of 123RF)

Bayer and Broad Institute Extend Research Collaboration to Develop New Cardiovascular Therapies

A research collaboration will focus on the joint discovery of novel therapeutic approaches based on findings in human genomics research related to cardiovascular diseases. Bayer (Berlin, Germany) and... Read more